Global Ganja Report

Manufacturers of vape cartridges filled with cannabis distillate for "dabbing" are facing something of a crisis as the market is flooded with counterfeit products. These contraband knock-offs are apparently fooling many consumers—but may contain toxin-laden and adulterated substances. Industry voices are urging buyers to beware.

The arrival of 7-10 as a special day to celebrate extracts and concentrates marks the growing embrace of "dabbing" by the cannabis community. But the laws governing such products and especially their production vary from state to state. And the real risks continue to garner grim headlines that cast the cannabis industry in a very poor light.

A Louisiana coroner declared a local woman's death to be the first on record attributed to a cannabis overdose, winning lurid national headlines. But medical experts and even federal officials as well as advocates are skeptical of the claim.

Finally settling a question that has vexed the Arizona medical marijuana program since it was launched nearly a decade ago, the state's highest court ruled that the program does indeed cover concentrates and extracts. The decision is a victory for patients who use edibles, tinctures or hashish.

Counterintuitively, the world's top legal cannabis producer, the United Kingdom, is now importing its first shipments of medicinal cannabis prodccts, from Canada and the Netherlands. This is an advance for the UK medical marijuana program, but a proverbial case of "coals to Newcastle"—pointing to the paradoxes of cannabis globalization.

After what has been an agonizing delay for many patients, Louisiana's first medical marijuana harvest has just cleared inspection. But there are still more hurdles before the first extracts and tinctures will begin arriving in the state's nine approved pharmacies. 

The World Health Organization has released its long-anticipated recommendation on cannabis scheduling. But rather than removing it from Schedule I of the Single Convention, it only removes it from Schedule IV, where it is also listed. CBD, however, has indeed been de-scheduled entirely.

In Arizona, the statehouse and supreme court are in a race to clarify whether hashish is to be included in the Grand Canyon State's medical marijuana program. The question also has implications for the status of extracts and edibles.